Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on Immunotherapy

9 listopada 2026 zaktualizowane przez: Tianjin Medical University Cancer Institute and Hospital

This study is a single-center, single-arm, prospective clinical study enrolling a total of 30 patients with advanced metastatic esophageal squamous cell carcinoma who have failed or progressed after prior first-line immunotherapy or immunotherapy combined with chemotherapy.

After signing the informed consent form, subjects will undergo screening assessment within 28 days prior to the first dose to determine whether they meet the study requirements. Subjects who meet the study inclusion and exclusion criteria will receive sacituzumab tirumotecan and a PD-1 inhibitor.

Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.

until investigator-confirmed radiological disease progression, unacceptable toxicity, the subject's request to discontinue treatment, or other protocol-specified criteria for treatment discontinuation, whichever occurs first; Eligible subjects will undergo regular tumor assessments based on RECIST 1.1. Within 48 weeks (within the first year) after dosing, imaging examinations for tumor assessment will be performed every 6 weeks (±7 days); after 48 weeks, tumor assessment will be performed every 12 weeks (±7 days), until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first. Imaging examinations will be performed as scheduled regardless of dose delay or adjustment. After a patient first achieves complete response (CR) or partial response (PR), the observed response must be confirmed at least 4 weeks (28 days) later.

For subjects who discontinue treatment for reasons other than radiological disease progression, death or loss to follow-up, imaging examinations should be repeated at the EOT visit if more than 4 weeks have elapsed since the previous imaging examination; subsequent imaging examinations should be performed as scheduled as far as possible until radiological disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent by the subject, loss to follow-up, death, or termination of the study by the sponsor, whichever occurs first.

After the end of treatment, regardless of whether a new anti-tumor therapy is initiated, safety follow-up must be completed for the subject, and survival follow-up visits will be continued by telephone every 3 months (±14 days) after the last dose of study treatment to obtain survival information and information on new anti-tumor therapy, until the subject decides to withdraw from the study, loss to follow-up, death, or the end of the study, whichever occurs first.

Przegląd badań

Status

Jeszcze nie rekrutacja

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

30

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Histopathologically confirmed unresectable advanced metastatic esophageal squamous cell carcinoma;
  2. Age 18-75 years, male or female;
  3. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (iRECIST 1.1); measurable lesions should not have received prior local therapy such as radiotherapy;
  4. Failure (disease progression or unacceptable toxicity) of prior first-line immunotherapy or immunotherapy combined with chemotherapy; patients who relapse within 6 months after the end of adjuvant/neoadjuvant therapy, if the treatment regimen was immunotherapy or immunotherapy combined with chemotherapy, will be regarded as having failed first-line treatment and may be enrolled;
  5. Expected survival of ≥12 weeks;
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before dosing;
  7. Radiologically confirmed disease progression during or after the most recent treatment for advanced or metastatic disease;
  8. Adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin or colony-stimulating factor within 2 weeks prior to the first dose)
  9. Female subjects of childbearing potential and male subjects whose partners are of childbearing potential must agree to use effective medical contraception from the signing of the informed consent form until 6 months after the last dose; 10) Subjects voluntarily participate in this study, sign the informed consent form, and are able to comply with the visits and related procedures specified in the protocol.

Exclusion Criteria:

  1. Subjects with known meningeal metastasis, brainstem metastasis, spinal metastasis and/or compression, or active or untreated central nervous system (CNS) metastasis. Subjects with brain metastasis who have received prior local therapy may be enrolled if they are clinically stable for at least 4 weeks before dosing and do not require glucocorticoids or anticonvulsants for at least 14 days;
  2. Patients who experienced disease progression within 3 months during prior first-line treatment;
  3. Prior receipt of TROP2-targeted therapy; prior receipt of any topoisomerase I inhibitor drug or chemotherapy;
  4. Presence of persistent or active infection;
  5. Participation in other anti-tumor drug clinical trials within 4 weeks before screening;
  6. Presence of adverse events of CTCAE > Grade 1 before the first dose (excluding alopecia and endocrine toxicity);
  7. Presence of other uncured malignancies within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
  8. Positive human immunodeficiency virus (HIV) test or a history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection;
  9. Known hypersensitivity to the study drug or any of its components;
  10. History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment, current ILD or non-infectious pneumonitis, or suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging examination at screening;
  11. Poorly controlled diabetes mellitus (fasting blood glucose ≥ 10 mmol/L on two consecutive measurements);
  12. Presence of clinically symptomatic pleural effusion, pericardial effusion or ascites requiring repeated drainage (> once per week);
  13. Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disease that prevents or delays corneal healing; Any condition that, in the investigator's judgment, interferes with the evaluation of the study drug, the safety of the subject or the interpretation of study results, or any other condition considered by the investigator to make the subject unsuitable for participation in this study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Sacituzumab tirumotecan combined with PD-1 inhibitor

Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.

Patients will receive sacituzumab tirumotecan (4 mg/kg IV d1 Q2W) in combination with a PD-1 inhibitor for 6 cycles, followed by maintenance therapy with a PD-1 inhibitor-based regimen.

Inne nazwy:
  • Inhibitor PD-1

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
progression-free survival (PFS)
Ramy czasowe: 2years

To evaluate progression-free survival (PFS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to radiologically confirmed disease progression (PD) (per iRECIST 1.1) or death from any cause without documented progression;

2years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
objective response rate (ORR)
Ramy czasowe: 1year

To evaluate the objective response rate (ORR) of sacituzumab tirumotecan combined with a PD-1 inhibitor: per iRECIST 1.1, the proportion of patients whose best overall response from enrollment to disease progression is CR or PR among all evaluable patients;

1year
overall survival (OS)
Ramy czasowe: 3years

To evaluate overall survival (OS) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from enrollment to death from any cause;

3years
duration of response (DOR)
Ramy czasowe: 1year

To evaluate the duration of response (DOR) with sacituzumab tirumotecan combined with a PD-1 inhibitor: the time from the first assessment meeting CR or PR criteria to the observation of PD or death, whichever occurs first; calculated only for patients whose best overall response is CR or PR

1year
adverse events (AEs)
Ramy czasowe: 2years

During this study and the follow-up period, the severity of adverse events will be graded and assessed according to NCI CTCAE (version 5.0). Safety evaluation indicators include:

The incidence, severity and relationship to the study drug of all adverse events (AEs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); The number and proportion of subjects with dose reduction and treatment discontinuation due to the above adverse events; Changes in vital signs, physical examination findings and laboratory results before, during and after study treatment.

2years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 grudnia 2026

Zakończenie podstawowe (Szacowany)

1 grudnia 2027

Ukończenie studiów (Szacowany)

1 grudnia 2028

Daty rejestracji na studia

Pierwszy przesłany

9 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 listopada 2026

Pierwszy wysłany (Rzeczywisty)

16 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj